Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arvinas Inc (NQ: ARVN )

26.15 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Arvinas Inc

< Previous 1 2 3 Next >
Do You Have Biotech FOMO? Why Cogent, Arvinas And Others Are Flying
Biotech stocks continued going gangbusters Wednesday. Here's why, experts say. 
Via Investor's Business Daily
7 Analysts Have This to Say About Arvinas
Arvinas (NASDAQ:ARVN) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 21, 2022
Upgrades 
Via Benzinga
Analyst Ratings for Arvinas
Arvinas (NASDAQ:ARVN) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Arvinas: Q1 Earnings Insights
Arvinas (NASDAQ:ARVN) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Expert Ratings For Arvinas
Arvinas (NASDAQ:ARVN) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 9, 2022
Upgrades 
Via Benzinga
What 6 Analyst Ratings Have To Say About Arvinas
Over the past 3 months, 6 analysts have published their opinion on Arvinas (NASDAQ:ARVN) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022
 
Via Benzinga
Arvinas: Q4 Earnings Insights
Arvinas (NASDAQ:ARVN) reported its Q4 earnings results on Monday, February 28, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
Analyst Ratings For Arvinas
Arvinas (NASDAQ:ARVN) has observed the following analyst ratings within th... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022
Upgrades 
Via Benzinga
Arvinas Earnings Perspective: Return On Capital Employed
Benzinga Pro data, Arvinas (NASDAQ:ARVN) reported Q4 sales of $26.30 million. Earnings fell to a loss of $53.00 million, resulting in a 13.35% decrease from last quarter. In Q3,... 
Via Benzinga
Expert Ratings For Arvinas
Within the last quarter, Arvinas (NASDAQ:ARVN) has observed the following ... 
Via Benzinga
Analyst Ratings For Arvinas
Over the past 3 months, 5 analysts have published their opinion on Arvinas (NASDAQ: 
Via Benzinga
Where Arvinas Stands With Analysts
Arvinas (NASDAQ:ARVN) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2... 
Via Benzinga
3 Stocks To Double Down On In 2022
The markets are entering somewhat uncertain territory, as the S&P 500 recently experienced its 39th correction since the beginning of 1950 due to a combination... 
Via Benzinga
Arvinas Highlights New ARV-110 Data In Prostate Cancer Patients
Arvinas Inc (NASDAQ: ARVN) announced the presentation of new data from completed Phase 1 dose-escalation and ongoing Phase 2 ARDENT expansion cohort with... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2022
Upgrades According to Gordon Haskett, the prior rating for Williams-Sonoma Inc (NYSE:WSM) was changed from Hold to Accumulate. Williams-Sonoma earned $3.32 in the third quarter,... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 19, 2022
Upgrades For Rocket Companies Inc (NYSE:RKT), JP Mo... 
Via Benzinga
5 Stocks Insiders Are Selling
When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to... 
Via Benzinga
Arvinas, Pfizer's ARV-471 Shows Clinical Benefit Rate Of 40% In Pretreated Breast Cancer Patients
Arvinas Inc (NASDAQ: ARVN) and Pfizer Inc (NYSE: PFE) posted updated data from Phase 1 dose-escalation trial of ARV-471 for locally advanced or... 
Via Benzinga
The Daily Biotech Pulse: Lilly Sings Metabolic Disorder Drug Pact, Moderna Reports Positive Flu Vaccine Data, Halozyme To Buy Back Shares
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Angion Biomedica's ANG-3777 Does Not Meet Primary Endpoint In Mid-Stage... 
Via Benzinga
4 Stocks Insiders Are Selling
When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 7, 2021
Upgrades For CarMax Inc (NYSE: 
Via Benzinga
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative... 
Via Benzinga
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2021
Upgrades According to Roth Capital, the prior rating for Ring Energy Inc (AMEX: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021
Upgrades For Cabot Oil & Gas Corp (NYSE:COG),... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2021
Upgrades According to Benchmark, the prior rating for TopBuild Corp (NYSE: 
Via Benzinga
The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.